{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-017680","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2022-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.700269+00:00","generated_at":"2026-06-27T15:32:48.309593+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Ikena Oncology appoints Richard Wooster to board of directors; board increases to 8","bullets":["Richard Wooster, Ph.D., appointed to fill new vacancy, effective Jan. 21, 2022; board expands from 7 to 8.","Wooster qualifies as independent director; receives option for 29,200 shares vesting over 3 years.","He brings 30+ years oncology drug discovery experience; discovered BRCA2 gene, co-discovered BRAF mutations.","Most recently CSO at Translate Bio (acquired by Sanofi 2021); previously VP at GSK."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-017680","json":"https://secwatch.observer/filing/0001193125-22-017680.json","markdown":"https://secwatch.observer/filing/0001193125-22-017680.md","text":"https://secwatch.observer/filing/0001193125-22-017680.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000119312522017680/0001193125-22-017680-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000119312522017680/d252798d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T15:32:48.309593+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"75791e0d48","claim":"Richard Wooster was appointed as Director at ImageneBio, Inc..","evidence_excerpt":"On January 21, 2022, the Board of Directors (the “Board”) of Ikena Oncology, Inc. (the “Company”) unanimously appointed Dr. Richard Wooster to fill a newly created vacancy on the Board resulting from an increase in the size of the Board from seven (7) to eight (8) directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835579/000119312522017680/0001193125-22-017680-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}